HMR starts trial of potential treatment for major symptoms of Alzheimer’s disease

Heptares announced in a press release today that the first subject has been dosed in this ‘phase 1 clinical study of novel selective muscarinic M₄ agonist in development to treat major symptoms of Alzheimer’s disease.’ ‘The compound stimulates M₄ receptor activity in the brain with high selectivity, and offers the possibility for an improved safety profile over previous muscarinic receptor agonists, which have been associated with adverse effects elsewhere in the body leading to safety and tolerability issues.’